Accelerating R&D at BSC BioNEST Bio-Incubator (BBB) and Bioriidl

Vaccines and Novel Biotherapeutics

Despite significant advances in medical science in the 21st century, infectious diseases continue to be the leading cause of morbidity and mortality worldwide. While the world continues to grapple with this challenge, a plethora of newly emerging and reemerging diseases render the situation acute. Some of these are zoonotic and result in pandemics of the kind we are witnessing with COVID-19, especially if transmission isn’t interrupted in time. Plus antigenic shifts and drifts pose a continuous threat to the effectiveness of the management options or interventions.

Vaccines and novel biotherapeutics are emerging as a promising domain to tackle these diseases, given their broad-based nature, with vaccines as prophylactics and monoclonal antibodies as therapeutics. However, the lack of infrastructure to develop and manufacture these necessary novel biologics threatens the developing world ability to tackle the problem effectively, often resulting in a far adverse impact.

Techinvention was founded with a mission to bring global health equity, especially to the developing world in the area of biologics. We fervently believe that ‘Access to essential and novel biologics should not be the privilege of only the affording few.’

To bring our mission to life, we offer strategic and technical advisory services to organizations of all types and sizes primarily in the developing world. Our advisory services include capacity building for development and manufacturing of vaccines and other novel biologics. In the short time since our founding, we have supported several initiatives of critical importance with successful project outcomes across Africa, Latin America and Asia.


BSC BioNEST Bio-Incubator (BBB)

We are incubated at the prestigious BSC BioNEST Bio-Incubator (BBB), Regional Centre for Biotechnology at NCR Biotech Science Cluster, Faridabad India to accelerate our indigenous novel biologics development program with contemporary recombinant platforms.


Bioriidl (Research Innovation Incubation Design Laboratories)

We are also incubated at Bioriidl (Research Innovation Incubation Design Laboratories) in Mumbai for the indigenous development of our vaccines and other biotherapeutics using appropriate platform technology. The incubation centre is supported by Department of Biotechnology (DBT) – Ministry of Science and Technology, Biotechnology Industry Research Assistance Council (BIRAC) and Government of India (GoI).

Genetically Engineered Lysins for Antimicrobial resistance (AMR)

Tuberculosis caused by Mycobacterium tuberculosis is a serious public health problem and is associated with high mortality and morbidity across the globe especially the developing countries. The emergence of multi drug-resistant (MDR) and extensively drug-resistant (XDR) strains, poor prognosis coupled with the economic and financial risks associated with developing novel antibiotics has posed significant challenges for the medicine man and the pharmaceutical industry.

Researchers have turned their spotlight on alternative therapies to treat this dreaded disease. Endolysins from mycobacteriophages serve as an effective weapon in the armamentarium to address the looming threat posed by drug resistant strains.

Techinvention has embarked on a journey to evaluate genetically engineered lysins derived from mycobacteriophages using appropriate platform technology against the MDR and XDR strains of M. tuberculosis.

The development of Lysins as promising antibacterial agents will offer novel insights in the pathogenesis as well as a paradigm shift in the management of tuberculosis. It will provide an invaluable solution to the Government of India’s initiative to eradicate tuberculosis by 2025. Our platform technology will also be used to evaluate lysins against other WHO prioritized ESKAPE pathogens and address the issue of antimicrobial resistance.

Intellectual Property

Techinvention is committed to protect, manage and leverage the various intellectual property (IP) assets across the business. Therefore, we are working consistently with our Research team to create innovative intellectual property of our products and processes in prophylactic and therapeutic areas. Intellectual property laws protect Techinvention’s valuable assets like patents, trademarks, regulatory data, copyrights, trade secrets, domain names and related rights.

We are in continuous process of adding new applications to increase IPR portfolio in the coming years. Presently we have filed 3 new applications on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on novel prophylactic candidate CoviTech™ and novel therapeutic candidate Techmab®. Techinvention is also working on engineering Novel Lyins formulation combination for the treatment of Mycobacterium tuberculosis and drug-resistant ESKAPE pathogens. Patent application is pending and due for publication.

Close Menu

We are pleased to announce that TechInvention has been selected in the alpha category for the Immersion-Collision Conference 2022 being held at the Enercare Centre, Toronto, Canada, on the 16th of June 2022 to the 25th June 2022.